Symic Bio

A new category of therapeutics based on extracellular matrix biology

General Information
Company Name
Symic Bio
Founded Year
2012
Location (Offices)
San Francisco, United States +1
Founders / Decision Makers
Number of Employees
2
Industries
Biotechnology, Health Care
Funding Stage
Series C
Social Media

Symic Bio - Company Profile

Symic Biomedical is a biotechnology startup founded in 2012 that focuses on empowering healing from within through innovative matrix regulator therapeutics for fibrosis, oncology, and central nervous system diseases. The company's treatments aim to influence matrix degradation and structure, connecting with damaged matrix targets caused by injury or disease to effectively reduce pathological inflammatory responses. Symic Biomedical's approach holds potential applications in fibrosis, oncology, and central nervous system disorders. The company recently secured a $11.00M Series C investment on 25 April 2019, with backing from Cell Innovation Partners, ReproCELL, and Shinsei Bank. This significant investment speaks to the confidence these industry players have in Symic Biomedical's mission and the promise of its innovative matrix regulator therapeutics. With its focus on critical areas within the healthcare industry, including oncology and central nervous system diseases, Symic Biomedical stands poised to make a meaningful impact in the field of biotechnology and health care.

Taxonomy: biomedical technology, therapeutics, matrix regulator, fibrosis treatment, oncology treatment, central nervous system disorders, inflammatory response modulation, medical research, biotech startup, innovative therapies, matrix degradation, disease treatment, clinical applications, biopharmaceuticals

Funding Rounds & Investors of Symic Bio (7)

View All
Funding Stage Amount No. Investors Investors Date
Series C $11.00M 3 Shinsei Bank, ReproCELL 25 Apr 2019
Series B $30.00M 3 Alex Popa 22 May 2017
Series A $25.00M 1 01 Dec 2015
Grant $1.50M 1 National Institutes of Health 27 Aug 2015
Series A $15.00M 2 05 Jan 2015

View All 7 Funding Rounds

Latest News of Symic Bio

View All

No recent news or press coverage available for Symic Bio.

Similar Companies to Symic Bio

View All
Alivio Therapeutics - Similar company to Symic Bio
Alivio Therapeutics Pioneering precision immunomodulation to tackle chronic and acute inflammatory disorders at their source.
Lixte Biotechnology Holdings, Inc. - Similar company to Symic Bio
Lixte Biotechnology Holdings, Inc. Lixte Biotechnology (Nasdaq: LIXT)
Eliaz Therapeutics Inc - Similar company to Symic Bio
Eliaz Therapeutics Inc A Therapeutic Intervention For Life-Threatening Diseases With No Effective Current Treatments